TY - JOUR
T1 - Microrna signatures associated with bronchopulmonary dysplasia severity in tracheal aspirates of preterm infants
AU - Siddaiah, Roopa
AU - Oji-Mmuo, Christiana N.
AU - Montes, Deborah T.
AU - Fuentes, Nathalie
AU - Spear, Debra
AU - Donnelly, Ann
AU - Silveyra, Patricia
N1 - Funding Information:
Funding: This research was funded by grants from Children’s Miracle Network (C.N.O-M., P.S.) 2013-2015, the Center for Research on Women and Newborn Health (R.S., P.S.) 2016-2017, and the Penn State College of Medicine Faculty Endowment Funds (R.S., C.N.O-M., P.S.) 2013-2020.
Funding Information:
This research was funded by grants from Children?s Miracle Network (C.N.O-M., P.S.) 2013-2015, the Center for Research on Women and Newborn Health (R.S., P.S.) 2016-2017, and the Penn State College of Medicine Faculty Endowment Funds (R.S., C.N.O-M., P.S.) 2013-2020. The authors thank Susan DiAngelo and Melody Pham for assistance with sample and data collection and Neal Thomas for protocol and IRB development guidance. The authors thank the Pennsylvania State University College of Medicine Genome Sciences Core Facility and the University of North Carolina at Chapel Hill Biobehavioral Laboratory for real-time PCR equipment.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in neonates as a consequence of preterm birth, arrested fetal lung development, and inflammation. The incidence of BPD remains on the rise as a result of increasing survival of extremely preterm infants. Severe BPD contributes to significant health care costs and is associated with prolonged hospitalizations, respiratory infections, and neurodevelopmental deficits. In this study, we aimed to detect novel biomarkers of BPD severity. We collected tracheal aspirates (TAs) from preterm babies with mild/moderate (n = 8) and severe (n = 17) BPD, and we profiled the expression of 1048 miRNAs using a PCR array. Associations with biological pathways were determined with the Ingenuity Pathway Analysis (IPA) software. We found 31 miRNAs differentially expressed between the two disease groups (2-fold change, false discovery rate (FDR) < 0.05). Of these, 4 miRNAs displayed significantly higher expression levels, and 27 miRNAs had significantly lower expression levels in the severe BPD group when compared to the mild/moderate BPD group. IPA identified cell signaling and inflammation pathways associated with miRNA signatures. We conclude that TAs of extremely premature infants contain miRNA signatures associated with severe BPD. These may serve as potential biomarkers of disease severity in infants with BPD.
AB - Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in neonates as a consequence of preterm birth, arrested fetal lung development, and inflammation. The incidence of BPD remains on the rise as a result of increasing survival of extremely preterm infants. Severe BPD contributes to significant health care costs and is associated with prolonged hospitalizations, respiratory infections, and neurodevelopmental deficits. In this study, we aimed to detect novel biomarkers of BPD severity. We collected tracheal aspirates (TAs) from preterm babies with mild/moderate (n = 8) and severe (n = 17) BPD, and we profiled the expression of 1048 miRNAs using a PCR array. Associations with biological pathways were determined with the Ingenuity Pathway Analysis (IPA) software. We found 31 miRNAs differentially expressed between the two disease groups (2-fold change, false discovery rate (FDR) < 0.05). Of these, 4 miRNAs displayed significantly higher expression levels, and 27 miRNAs had significantly lower expression levels in the severe BPD group when compared to the mild/moderate BPD group. IPA identified cell signaling and inflammation pathways associated with miRNA signatures. We conclude that TAs of extremely premature infants contain miRNA signatures associated with severe BPD. These may serve as potential biomarkers of disease severity in infants with BPD.
UR - http://www.scopus.com/inward/record.url?scp=85102710087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102710087&partnerID=8YFLogxK
U2 - 10.3390/biomedicines9030257
DO - 10.3390/biomedicines9030257
M3 - Article
C2 - 33807742
AN - SCOPUS:85102710087
SN - 2227-9059
VL - 9
SP - 1
EP - 16
JO - Biomedicines
JF - Biomedicines
IS - 3
M1 - 257
ER -